摘要
目的探讨HBV感染者血清中乙肝表面抗原大蛋白(HBV-LP)水平对HBV复制状态的判定和对临床抗病毒治疗的指导意义。方法对90例接受抗病毒治疗的慢性HBV患者,采用酶联免疫吸附试验(ELISA)和荧光定量PCR法定期进行血清HBV-LP和HBV DNA定量检测,对检测数据进行相关性分析。结果抗病毒治疗前90例次感染血清中HBV-LP与HBV DNA检出阳性率差异无显著性(P>0.05)。检测210例次感染血清中,HBV-LP含量与HBV DNA具有良好的相关关系(r=0.857,P=0.000),HBV-LPOD值和HBV DNA拷贝数随抗病毒治疗时间的延长同步下降。结论血清中HBV-LP能反映体内HBV复制水平,抗病毒治疗过程中HBV-LP和HBV DNA同步下降,可用于判断HBV复制程度和用于指导抗病毒治疗。
Objective To evaluate the clinical signification of hepatitis B virus large protein （ HBV - LP） serum levels in the prediction of HBV DNA replication state and estimation of the efficacy of antivirus treatment. Methods Serum samples were collected from 90 patients with HBV infection. HBV - LP was examined using enzyme linked immunosorbent assay （ELISA）. HBV DNA was quantitatively determined by real time polymerase chain reaction. The collected data were analyzed with bi -variate correlations method. Results There was no significant difference between the detectable rates of HBV DNA and HBVLP in 90 blood samples before treatment（ P 〉 0.05 ） ; The levels of serum HBV - LP was positively correlated with HBV DNA copies（ r = 0. 857 ,P = 0. 000）in total 210 blood samples . HBV - LP OD and HBV DNA replication decreased simultaneously with time following anti - viral treatment. Conclusion The levels of serum HBV - LP and the copies of HBV DNA decrease during the antivirus treatment, suggesting that serum HBV - LP can be used to estimate the state of HBV DNA replication and predict the effect of treatment.
出处
《广东医学》
CAS
CSCD
北大核心
2009年第2期211-212,共2页
Guangdong Medical Journal
基金
广东省深圳市福田区公益性科研计划项目(编号:FTWS081)
